NEWS AND MEDIA
Our Commitment to Safety as we Navigate Coronavirus
Mar 24, 2020
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.
Speaking Out Against Systemic Racism
June 3, 2020
WE FEEL compelled at this moment to speak out about the unacceptable and disturbing acts of racial injustice that have brought our nation to an inflection point.
WE BELIEVE that any form of racism or racial suppression is wrong. We believe that addressing injustice must be a priority for us all. We believe that people have the right to protest peacefully. We believe that compassion and understanding happen only when we truly open our hearts and listen.
WE WILL do our part. We will continue to provide a safe and welcoming environment for our employees. We will foster an environment that encourages open dialogue, opportunities, and support for individuals from all backgrounds. We will not tolerate racial discrimination or harassment in our ranks. We will continue to support organizations that provide services for underserved populations in communities where we live, work and serve. And we will listen so we can do better in honoring these commitments.
Recent News
Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that…
Purdue Pharma Urges Accuracy in Communications on Abuse-Deterrent Formulations of Opioids
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is deeply concerned…
Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual ConferenceResults Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. –…
Purdue Pharma L.P. to Present Data from Three Research Studies at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual ConferenceStudies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September 6, 2018 – Purdue…
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive, Over-the-Counter, Life-Saving Naloxone in the United States
STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced that Purdue is providing a $3.42 million grant to Harm Reduction Therapeutics to advance the development of its low-cost,…
Prescription Drug Safety Curriculum Increased Student Knowledge by 49 Percent in its Inaugural Academic Year
Purdue Expands Established Commitment to Include a Statewide Education Program in Collaboration with EVERFI and Connecticut Prevention Network for the 2018-2019 Academic Year STAMFORD, Conn., August 15, 2018 — Purdue Pharma L.P. today announced that, through its…
Purdue Pharma L.P. Issues Statement on Opioid Promotion
STAMFORD, Conn. – February 9, 2018 – Purdue Pharma L.P. issued the following statement today: We have restructured and significantly reduced our commercial operation and our sales representatives will no longer promote opioids to prescribers. Going forward, questions…
Purdue Pharma L.P. Awards Grants to Further Research on the Assessment of Chronic Pain
Research includes study of Virtual Reality technology as potential tool in chronic pain assessment STAMFORD, Conn. – January 31, 2018 – Purdue Pharma L.P. today announced the funding of three grants for investigator-initiated research on developing clinically relevant…